Here is a brief preview of this blast: Glooko announced it has appointed Mark Clements as the company's new CMO. Recall, Clements is a pediatric endocrinologist from Kansas City, MO who has sat on the Glooko board since 2015. He also served as the Pediatric Chair of T1D Exchange. Below, FENIX provides insight into how Clements fits into Glooko's business needs.
About The Author
Matthew Maryniak
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.